Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 10:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1129–1152 of 50,362 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cancer Clear all
Completed Phase 3 Interventional Results available

An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age

NCT01151410
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren, Enalapril
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years to 17 Years
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
17
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2016 · Synced Oct 30, 2026, 10:26 AM EDT
Completed Phase 1 Interventional

A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer

NCT02122913
View directory record Official record
Conditions
Solid Tumors Harboring NTRK Fusion
Interventions
Larotrectinib (Vitrakvi, BAY2757556)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
8
States / cities
Aurora, Colorado • Boston, Massachusetts • Cleveland, Ohio + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 30, 2026, 10:26 AM EDT
Completed Not applicable Interventional

Evaluation of Sun Protection Education for Kidney Transplant Recipients

NCT01844713
View directory record Official record
Conditions
Unspecified Complications of Kidney Transplant, Disorder Related to Renal Transplantation
Interventions
Workbook
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 85 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 1, 2014 · Synced Oct 30, 2026, 10:26 AM EDT
Terminated Phase 2 Interventional Results available

Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23)

NCT01253460
View directory record Official record
Conditions
Leukemia
Interventions
Cyclophosphamide, Rituximab, Sapacitabine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 6, 2019 · Synced Oct 30, 2026, 10:26 AM EDT
Completed Phase 1 Interventional Results available

Pembrolizumab and Concurrent Chemoradiotherapy or Radiation Therapy in Treating Patients With Small Cell Lung Cancer

NCT02402920
View directory record Official record
Conditions
Extensive Stage Small Cell Lung Carcinoma, Limited Stage Small Cell Lung Carcinoma, Neuroendocrine Neoplasm
Interventions
Carboplatin, Cisplatin, Etoposide, Laboratory Biomarker Analysis, Pembrolizumab, Radiation Therapy
Drug · Other · Biological + 1 more
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 30, 2026, 10:26 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Calibration of MR and PET-MR Imaging Protocols at RIC

NCT02249520
View directory record Official record
Conditions
Cancer, Coronary Artery Disease
Interventions
PET-MR imaging on Biograph mMR scanner, MR-only imaging on Biograph mMR scanner, MR imaging on the Siemens Vida 3T MR scanner
Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2040
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 21, 2024 · Synced Oct 30, 2026, 10:26 AM EDT
Completed Phase 1 Interventional

An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers

NCT03956680
View directory record Official record
Conditions
Advanced Solid Cancers
Interventions
BMS-986301, Nivolumab, Ipilimumab
Drug · Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
4
States / cities
Chicago, Illinois • St Louis, Missouri • Pittsburgh, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Oct 30, 2026, 10:26 AM EDT
Terminated Phase 2 Interventional Results available

CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer

NCT03002623
View directory record Official record
Conditions
Thyroid Neoplasms, Poorly Differentiated and Undifferentiated Thyroid Cancer, Differentiated Thyroid Cancer
Interventions
CUDC-907
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 21, 2018 · Synced Oct 30, 2026, 10:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Facilitating Parent Adaptation to Pediatric Transplant: The P-SCIP Trial

NCT00939380
View directory record Official record
Conditions
Childhood Cancers
Interventions
Behavioral intervention sessions, CD-ROM, DVD and pamphlet, Respite care
Behavioral · Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
212 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
5
States / cities
Los Angeles, California • Atlanta, Georgia • New Brunswick, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2016 · Synced Oct 30, 2026, 10:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Using Connected Health to Increase Lung Cancer Screening

NCT04612946
View directory record Official record
Conditions
Lung Cancer
Interventions
Referral to Telemedicine LCS Counseling Visit, Usual Care
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
55 Years to 77 Years
Enrollment
137 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 7, 2022 · Synced Oct 30, 2026, 10:26 AM EDT
Completed Not applicable Interventional

Remote Ischemic Conditioning in Oncology

NCT04805346
View directory record Official record
Conditions
Participants Undergoing Anthracycline Chemotherapy
Interventions
autoRIC®
Device
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
11 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 26, 2024 · Synced Oct 30, 2026, 10:26 AM EDT
Completed Phase 1 Interventional

α-TEA in Advanced Cancer

NCT02192346
View directory record Official record
Conditions
Metastatic Carcinoma, Metastatic Sarcoma, Metastatic Lymphoma
Interventions
2.4 mg/kg α-TEA, 4.8 mg/kg α-TEA, 8.0 mg/kg α-TEA, 9.6 mg/kg α-TEA, 12 mg/kg α-TEA, 16.8 mg/kg α-TEA, 19.2 mg/kg α-TEA, 22.3 mg/kg α-TEA, 26.8 mg/kg α-TEA
Drug
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
5
States / cities
Clackamas, Oregon • Newberg, Oregon • Oregon City, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2018 · Synced Oct 30, 2026, 10:26 AM EDT
Withdrawn Phase 2 Interventional

12-week Study of NFX-179 Gel in Subjects With Epidermal Nevi

NCT05195762
View directory record Official record
Conditions
Epidermal Nevi, Nevus Sebaceus
Interventions
NFX-179 Gel 1.50%
Drug
Lead sponsor
Albert Chiou
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Redwood City, California
Source: ClinicalTrials.gov public record
Updated May 28, 2024 · Synced Oct 30, 2026, 10:26 AM EDT
Recruiting No phase listed Observational

Prostate Ablation Registry and Database for Information, Surveillance, and Evaluation (PARADISE)

NCT06705803
View directory record Official record
Conditions
Prostate Cancer
Interventions
Prostate Ablation
Procedure
Lead sponsor
University of Chicago
Other
Eligibility
22 Years and older · Male only
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
2
States / cities
Hyde Park, Illinois • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Oct 30, 2026, 10:26 AM EDT
Completed Not applicable Interventional Results available

Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy

NCT05152927
View directory record Official record
Conditions
Parathyroid Diseases, Parathyroid Dysfunction, Parathyroid Neoplasms, Parathyroid Adenoma, Hypercalcemia, Neoplasms, Glandular and Epithelial, Endocrine Gland Neoplasms, Adenoma, Hyperparathyroidism, Hyperparathyroidism, Primary
Interventions
Parathyroid Eye (PTeye)
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 30, 2026, 10:26 AM EDT
Completed Not applicable Interventional

OPTimizing Treatment Focused Genetic Testing IN Cancer

NCT04066361
View directory record Official record
Conditions
Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer
Interventions
Chatbot, Video Education
Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 25, 2024 · Synced Oct 30, 2026, 10:26 AM EDT
Recruiting Not applicable Interventional

Helping Men Adhere to Sexual Rehabilitation Following Prostate Cancer Surgery

NCT02706561
View directory record Official record
Conditions
Prostate Cancer, Erectile Dysfunction
Interventions
questionnaires, three in-person sessions, monthly phone calls, Acceptance and Commitment Therapy for Erectile Dysfunction (ACT-ED), Enhanced Monitoring and Education (EME)
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older · Male only
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 30, 2026, 10:26 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC

NCT05682443
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
ONC-392 low, ONC-392 high, lutetium Lu 177 vipivotide tetraxetan
Drug
Lead sponsor
OncoC4, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
23
States / cities
Sacramento, California • Aurora, Colorado • Tampa, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 30, 2026, 10:26 AM EDT
Terminated Phase 2 Interventional Results available

Phase II Docetaxel / Carboplatin / XRT + Surgical Resection in Stage III NSCLC

NCT00238615
View directory record Official record
Conditions
Lung Cancer, Carcinoma, Non-Small-Cell Lung
Interventions
Docetaxel, Carboplatin, Radiation therapy, Surgical resection
Drug · Procedure
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2014
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 12, 2015 · Synced Oct 30, 2026, 10:26 AM EDT
Terminated Phase 1 Interventional

A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma

NCT02978235
View directory record Official record
Conditions
Multiple Myeloma, NonHodgkin Lymphoma
Interventions
TAS4464
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
7
States / cities
Bethesda, Maryland • Boston, Massachusetts • Farmington Hills, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2024 · Synced Oct 30, 2026, 10:26 AM EDT
Active, not recruiting No phase listed Observational

Parental Decision-Making for Children With Relapsed Neuroblastoma

NCT02282735
View directory record Official record
Conditions
Relapsed Neuroblastoma
Interventions
Not listed
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
9
States / cities
Los Angeles, California • Palo Alto, California • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 30, 2026, 10:26 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic Cancer

NCT00039676
View directory record Official record
Conditions
Waldenstrom Macroglobulinemia, Chronic Lymphocytic Leukemia, Hodgkin Disease, NonHodgkin Lymphoma, Mixed Lymphoproliferative Disease
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
11 Months and older
Enrollment
1,836 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2002
U.S. locations
2
States / cities
Bethesda, Maryland • Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Oct 30, 2026, 10:26 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Fujifilm DBT Plus S-View Versus FFDM Alone in the Detection of Breast Cancer

NCT03491917
View directory record Official record
Conditions
Breast Cancer
Interventions
DBT plus S-View, FFDM alone
Device
Lead sponsor
Fujifilm Medical Systems USA, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Norwalk, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 18, 2020 · Synced Oct 30, 2026, 10:26 AM EDT
Recruiting Phase 1 Interventional

Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

NCT05372640
View directory record Official record
Conditions
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic NUT Carcinoma, Unresectable Breast Carcinoma, Unresectable Malignant Solid Neoplasm, Unresectable NUT Carcinoma
Interventions
Abemaciclib, BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure, Biospecimen Collection, Diagnostic Imaging Testing
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
7
States / cities
Los Angeles, California • Newport Beach, California • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 30, 2026, 10:26 AM EDT